Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-028436
Filing Date
2021-05-17
Accepted
2021-05-17 16:41:20
Documents
52
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-10q_20210331.htm   iXBRL 10-Q 934414
2 EX-31.1 ikt-ex311_140.htm EX-31.1 10203
3 EX-31.2 ikt-ex312_139.htm EX-31.2 10226
4 EX-32.1 ikt-ex321_137.htm EX-32.1 8445
5 EX-32.2 ikt-ex322_138.htm EX-32.2 7939
  Complete submission text file 0001564590-21-028436.txt   3457089

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ikt-20210331.xsd EX-101.SCH 33093
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ikt-20210331_cal.xml EX-101.CAL 28126
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ikt-20210331_def.xml EX-101.DEF 72813
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20210331_lab.xml EX-101.LAB 233912
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20210331_pre.xml EX-101.PRE 173367
11 EXTRACTED XBRL INSTANCE DOCUMENT ikt-10q_20210331_htm.xml XML 427419
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 21931569
SIC: 2836 Biological Products, (No Diagnostic Substances)